Please ensure Javascript is enabled for purposes of website accessibility

Should You Buy These 3 Dirt-Cheap Stocks?

By Keith Speights - Mar 26, 2020 at 7:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A stock can be cheap but not be a bargain. At least two of these stocks appear to be both.

There are a lot of stocks that are much cheaper than they've been in a while. That doesn't necessarily make them cheap, though. Think about it this way: Someone could cut the price of a pet rock from $10,000 to $5,000, but it still wouldn't be a bargain. 

However, there are some stocks that really do appear to be inexpensive right now. Three in the healthcare sector that stand out are Alexion Pharmaceuticals (ALXN), Cigna (CI), and HCA Healthcare (HCA 2.76%). But should you buy these dirt-cheap stocks?

A man scratching his head while staring at drawings of question marks and money bags on the wall in front of him

Image source: Getty Images.

1. Alexion Pharmaceuticals

Alexion's shares currently trade at around 7.5 times expected earnings. Its price-to-earnings-to-growth (PEG) ratio is a really low 0.57. Any stock with a PEG below 1.0 is generally viewed as attractively priced. You won't find too many stocks with as low of a valuation that also delivered 20% revenue growth last year along with astronomical earnings growth. 

There's a reason Alexion's shares are so inexpensive, though. Nearly 80% of the biotech's total product sales come from one drug: Soliris. And while the drug has been a runaway success for Alexion, its perch at the top could be threatened.

It's unknown how much longer Soliris will enjoy patent exclusivity. Alexion is appealing the revoking of a key European patent for the drug. One key U.S. patent expires in 2021, although the company has other patents that go through 2027. In addition, Apellis Pharmaceuticals reported positive late-stage results earlier this year for pegcetacoplan, which beat Soliris in a head-to-head matchup in treating rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH) -- an important indication for Soliris.

However, Alexion has its own replacement for Soliris that's picking up significant momentum with Ultomiris. The company's acquisition of Achillion gives it a promising Factor D program. Wall Street analysts project that Alexion's earnings will grow by 13% annually over the next five years, slower than in the past, but still solid. My view is that Alexion is a biotech stock worth buying at its discounted price.

2. Cigna

Cigna appears to be the most attractively priced health insurance stock on the market right now. Its stock trades at less than 10 times expected earnings with a PEG ratio of 0.85. 

It's not surprising that Cigna's shares have been clobbered more than the S&P 500 index during the market crash. The company's bottom line could take a hit if the coronavirus pandemic causes medical costs to rise significantly, which could very well happen with large numbers of COVID-19 cases in the U.S.

Most of Cigna's year-over-year growth in the fourth quarter stemmed from its acquisition of pharmacy benefits manager Express Scripts. However, the company's core insurance businesses also performed well thanks to gaining additional members and premium increases.

The existential threat that Medicare for All proposals might have presented for Cigna seems to have practically evaporated with former Vice President Joe Biden's commanding lead in delegates for the Democratic presidential nomination. However, health insurers could still come under fire regardless of who sits in the Oval Office beginning in 2021. Although Cigna is dirt-cheap right now, my view is that there are better stocks to buy with fewer potential headwinds.

3. HCA Healthcare

HCA Healthcare's shares have been hammered harder than any of these three stocks. But this shellacking has made the hospital operator look really inexpensive, with shares trading at less than nine times expected earnings. HCA's PEG ratio stands at 0.91.

Hospitals across the U.S. are already feeling a major impact from COVID-19. It will almost certainly get much worse before it gets better. The coronavirus pandemic is also causing hospitals to postpone elective surgeries that are often relatively lucrative.

As the nation's largest hospital operator, HCA could be affected more heavily by the coronavirus outbreak than its smaller peers. However, the company could also have help on the way. A major stimulus bill that would steer billions of dollars to hospitals seems likely to pass in both houses of the U.S. Congress and be signed into law by President Trump.

Is this beaten-down hospital stock a bargain worth buying right now? I normally wouldn't be a fan of HCA Healthcare as an investment, but we're in a period that isn't normal, to say the least. I think the stock will bounce back once the crisis is over and should deliver tremendous gains to patient investors.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN
Cigna Corporation Stock Quote
Cigna Corporation
CI
HCA Healthcare, Inc. Stock Quote
HCA Healthcare, Inc.
HCA
$182.33 (2.76%) $4.89
Apellis Pharmaceuticals, Inc. Stock Quote
Apellis Pharmaceuticals, Inc.
APLS
$46.26 (-1.57%) $0.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.